Literature DB >> 14638485

Artemether bioavailability after oral or intramuscular administration in uncomplicated falciparum malaria.

Kamolrat Silamut1, Paul N Newton, Paktiya Teja-Isavadharm, Yupin Suputtamongkol, Duangsuda Siriyanonda, Maneerat Rasameesoraj, Sasithon Pukrittayakamee, Nicholas J White.   

Abstract

The antimalarial activity of artemether following oral or intramuscular administration in the plasma of 15 adults with acute uncomplicated Plasmodium falciparum malaria was measured by bioassay. The peak concentrations in plasma following oral administration were higher in patients with acute illness (median, 1,905 mmol of dihydroartemisinin [DHA] equivalents per liter; range, 955 to 3,358 mmol of DHA equivalents per liter) than in patients in the convalescent phase (median, 955 mmol of DHA equivalents per liter; range, 576 to 1,363 mmol of DHA equivalents per liter), and clearance (CL/F) was lower in patients in the acute phase (1.11 liters/kg/h; range, 0.21 to 3.08 liters/kg/h) than in patients in the convalescent phase (median, 2.76 liters/kg/h; range, 1.56 to 5.74 liters/kg/h) (P< or =0.008). Antimalarial activity in terms of the peak concentration in plasma (Cmax) after oral administration was a median of 16 times higher than that after intramuscular administration. The ratio of the area under the plasma concentration-time curve during the first 24 h (AUC(0-24)) after oral administration of artemether to the AUC(0-24) after intramuscular administration was a median of 3.3 (range, 1 to 11) (P=0.0001). In the acute phase, the time to Cmax was significantly shorter after oral administration (median, 1 h; range, 0.5 to 3.0 h) than after intramuscular administration (median, 8 h; range, 4 to 24 h) (P=0.001). Intramuscular artemether is absorbed very slowly in patients with acute malaria.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14638485      PMCID: PMC296187          DOI: 10.1128/AAC.47.12.3795-3798.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  19 in total

Review 1.  Severe and complicated malaria. World Health Organization, Division of Control of Tropical Diseases.

Authors: 
Journal:  Trans R Soc Trop Med Hyg       Date:  1990       Impact factor: 2.184

2.  A meta-analysis using individual patient data of trials comparing artemether with quinine in the treatment of severe falciparum malaria.

Authors: 
Journal:  Trans R Soc Trop Med Hyg       Date:  2001 Nov-Dec       Impact factor: 2.184

3.  A simple method for assessing quinine pre-treatment in acute malaria.

Authors:  K Silamut; R Hough; T Eggelte; S Pukrittayakamee; B Angus; N J White
Journal:  Trans R Soc Trop Med Hyg       Date:  1995 Nov-Dec       Impact factor: 2.184

4.  Clinical pharmacokinetics and pharmacodynamics of artemisinin and derivatives.

Authors:  N J White
Journal:  Trans R Soc Trop Med Hyg       Date:  1994-06       Impact factor: 2.184

5.  A comparison of oral artesunate and artemether antimalarial bioactivities in acute falciparum malaria.

Authors:  Y Suputtamongkol; P N Newton; B Angus; P Teja-Isavadharm; D Keeratithakul; M Rasameesoraj; S Pukrittayakamee; N J White
Journal:  Br J Clin Pharmacol       Date:  2001-12       Impact factor: 4.335

6.  Dose-finding and efficacy study for i.m. artemotil (beta-arteether) and comparison with i.m. artemether in acute uncomplicated P. falciparum malaria.

Authors:  S Looareesuwan; B Oosterhuis; B M Schilizzi; F A E Sollie; P Wilairatana; S Krudsood; Ch B Lugt; P A M Peeters; J O Peggins
Journal:  Br J Clin Pharmacol       Date:  2002-05       Impact factor: 4.335

7.  Comparative pharmacokinetics of intramuscular artesunate and artemether in patients with severe falciparum malaria.

Authors:  T T Hien; T M E Davis; L V Chuong; K F Ilett; D X T Sinh; N H Phu; C Agus; G M Chiswell; N J White; J Farrar
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

8.  Comparison of oral artesunate and dihydroartemisinin antimalarial bioavailabilities in acute falciparum malaria.

Authors:  Paul N Newton; Michele van Vugt; Paktiya Teja-Isavadharm; Duangsuda Siriyanonda; Maneerat Rasameesoroj; Pramote Teerapong; Ronatrai Ruangveerayuth; Thra Slight; Francois Nosten; Yupin Suputtamongkol; Sornchai Looareesuwan; Nicholas J White
Journal:  Antimicrob Agents Chemother       Date:  2002-04       Impact factor: 5.191

9.  Randomized comparison of artesunate and quinine in the treatment of severe falciparum malaria.

Authors:  Paul N Newton; Brian J Angus; Wirongrong Chierakul; Arjen Dondorp; Ronatrai Ruangveerayuth; Kamolrat Silamut; Pramote Teerapong; Yupin Suputtamongkol; Sornchai Looareesuwan; Nicholas J White
Journal:  Clin Infect Dis       Date:  2003-06-23       Impact factor: 9.079

10.  A controlled trial of artemether or quinine in Vietnamese adults with severe falciparum malaria.

Authors:  T H Tran; N P Day; H P Nguyen; T H Nguyen; T H Tran; P L Pham; X S Dinh; V C Ly; V Ha; D Waller; T E Peto; N J White
Journal:  N Engl J Med       Date:  1996-07-11       Impact factor: 91.245

View more
  11 in total

1.  Pharmacokinetics of a novel sublingual spray formulation of the antimalarial drug artemether in healthy adults.

Authors:  Sam Salman; Daryl Bendel; Toong C Lee; David Templeton; Timothy M E Davis
Journal:  Antimicrob Agents Chemother       Date:  2015-03-23       Impact factor: 5.191

2.  Mechanisms of artemether toxicity on single cardiomyocytes and protective effect of nanoencapsulation.

Authors:  Ana Carolina Moreira Souza; Andrea Grabe-Guimarães; Jader Dos Santos Cruz; Artur Santos-Miranda; Charlotte Farah; Liliam Teixeira Oliveira; Alexandre Lucas; Franck Aimond; Pierre Sicard; Vanessa Carla Furtado Mosqueira; Sylvain Richard
Journal:  Br J Pharmacol       Date:  2020-08-24       Impact factor: 8.739

Review 3.  Artemisinins.

Authors:  C J Woodrow; R K Haynes; S Krishna
Journal:  Postgrad Med J       Date:  2005-02       Impact factor: 2.401

4.  Interspecies allometric scaling of antimalarial drugs and potential application to pediatric dosing.

Authors:  S M D K Ganga Senarathna; Kevin T Batty
Journal:  Antimicrob Agents Chemother       Date:  2014-08-04       Impact factor: 5.191

5.  Impaired clinical response in a patient with uncomplicated falciparum malaria who received poor-quality and underdosed intramuscular artemether.

Authors:  Valy Keoluangkhot; Michael D Green; Leonard Nyadong; Facundo M Fernández; Mayfong Mayxay; Paul N Newton
Journal:  Am J Trop Med Hyg       Date:  2008-04       Impact factor: 2.345

6.  Disposition of artesunate and dihydroartemisinin after administration of artesunate suppositories in children from Papua New Guinea with uncomplicated malaria.

Authors:  Harin A Karunajeewa; Kenneth F Ilett; Kitiya Dufall; Adedayo Kemiki; Moses Bockarie; Michael P Alpers; P Hugh Barrett; Paolo Vicini; Timothy M E Davis
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

7.  Artesunate suppositories versus intramuscular artemether for treatment of severe malaria in children in Papua New Guinea.

Authors:  Harin A Karunajeewa; John Reeder; Kerry Lorry; Elizah Dabod; Juliana Hamzah; Madhu Page-Sharp; Gregory M Chiswell; Kenneth F Ilett; Timothy M E Davis
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

8.  Efficacy and safety of artemether against a natural Fasciola hepatica infection in sheep.

Authors:  Jennifer Keiser; Laura Rinaldi; Vincenzo Veneziano; Laura Mezzino; Marcel Tanner; Jürg Utzinger; Giuseppe Cringoli
Journal:  Parasitol Res       Date:  2008-05-15       Impact factor: 2.289

9.  Post-Marketing Surveillance of Quality of Artemether Injection Marketed in Southwest Nigeria.

Authors:  Ibrahim A Hassan; Adebanjo J Adegbola; Julius O Soyinka; Cyprian O Onyeji; Oluseye O Bolaji
Journal:  Am J Trop Med Hyg       Date:  2020-09       Impact factor: 2.345

10.  Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial.

Authors:  Arjen M Dondorp; Caterina I Fanello; Ilse C E Hendriksen; Ermelinda Gomes; Amir Seni; Kajal D Chhaganlal; Kalifa Bojang; Rasaq Olaosebikan; Nkechinyere Anunobi; Kathryn Maitland; Esther Kivaya; Tsiri Agbenyega; Samuel Blay Nguah; Jennifer Evans; Samwel Gesase; Catherine Kahabuka; George Mtove; Behzad Nadjm; Jacqueline Deen; Juliet Mwanga-Amumpaire; Margaret Nansumba; Corine Karema; Noella Umulisa; Aline Uwimana; Olugbenga A Mokuolu; Olanrewaju T Adedoyin; Wahab B R Johnson; Antoinette K Tshefu; Marie A Onyamboko; Tharisara Sakulthaew; Wirichada Pan Ngum; Kamolrat Silamut; Kasia Stepniewska; Charles J Woodrow; Delia Bethell; Bridget Wills; Martina Oneko; Tim E Peto; Lorenz von Seidlein; Nicholas P J Day; Nicholas J White
Journal:  Lancet       Date:  2010-11-07       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.